NASDAQ$LUNG

Pulmonx Corporation · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Achieved record revenue and gross margin as procedure volumes began to normalize across key markets.

Pulmonx Corporation reported a significant increase in revenue for the second quarter of 2021, with worldwide revenue reaching $12.2 million, a 232% increase compared to the same period last year. The company's gross margin also improved significantly, reaching 74% compared to 28% in the second quarter of 2020. They are updating its full year 2021 revenue guidance to be in the range of $49 to $51 million.

  • Worldwide revenue increased by 232% to $12.2 million in the second quarter of 2021 compared to the same period last year.
  • Gross margin reached 74% in the second quarter of 2021, a significant increase from 28% in the same period last year.
  • 20 new U.S. Zephyr® Valve treating centers were added, bringing the total to 180.
  • A software upgrade for Chartis® was launched to enable simpler and faster patient assessment of collateral ventilation.

Headline financials

Total Revenue

$12.2M

Previous: $3.67M+232.2%
EPS (adj)

-$0.34

Previous: $27.67-101.2%
Capital Expenditures

-$903K

Previous: $61K-1580.3%
Free Cash Flow

-$13.3M

Previous: -$7.75M-71.3%
Net Income

-$12.4M

Previous: -$11.9M-3.9%
Operating Income

-$12.1M

Previous: -$11.5M-5.0%
Gross Profit

$9.03M

Previous: $1.01M+792.2%
Cash & Equivalents

$199M

Previous: $43.3M+358.4%
Total Assets

$249M

No prior period
Stock-Based Comp

$2.31M

Previous: $159K+1354.1%

Revenue & EPS history

Pulmonx · Revenue · Quarterly

$12.2M

Q2 2021+232.2%vs Q2 2020
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Forward guidance

Pulmonx is updating its full year 2021 revenue guidance to be in the range of $49 to $51 million. Pulmonx continues to expect total operating expenses for the full year 2021 to remain in the range of $85 to $90 million inclusive of stock-based compensation.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-3.4%

Avg return

Earnings day

-4.1%

Avg return

5 days after

-5.3%

Avg return

30 days after

42%

10 / 24 earnings

Positive

+32.2%

Q4 2024

Best reaction

-64.7%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-6.7%+12.6%
Q4 2025+0.6%-6.1%-28.2%
Q3 2025-18.9%-28.6%+29.1%
Q1 2025-21.9%-28.8%-29.6%
Q4 2024+32.2%+30.7%+17.0%
Q3 2024-7.7%+5.2%-4.7%
Q2 2024-8.1%-15.4%+3.7%
Q1 2024+23.3%+21.9%-4.7%
Q4 2023-17.7%-27.9%-36.1%
Q3 2023+6.9%+20.7%+34.2%
Q2 2023-4.1%-8.0%-26.0%
Q1 2023+1.1%-0.2%-1.5%
Q4 2022+20.8%+26.0%+27.1%
Q3 2022-64.7%-61.1%-52.3%
Q2 2022+9.2%+19.9%+5.7%
Q1 2022+0.6%-23.6%-23.9%
Q4 2021-6.9%-2.5%-12.5%
Q3 2021+7.1%+12.6%-23.7%
Q2 2020-7.6%-10.9%-1.6%
Q2 2021+0.1%+6.0%+3.3%
Q1 2020-5.8%-5.3%+9.9%
Q1 2021-8.7%-9.6%-10.3%
Q4 2020-4.1%-3.4%-20.2%
Q3 2020-4.9%-3.4%+5.6%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro